Alvotech (ALVO) vs Maze Therapeutics (MAZE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Maze Therapeutics (MAZE) has outperformed Alvotech (ALVO) over the past year, losing 13.5% versus a loss of 19.8%. Maze Therapeutics is the larger company by market cap ($1.72 billion vs $1.47 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALVO | MAZE |
|---|---|---|
| Share price | $4.12 | $31.37 |
| Market cap | $1.47B | $1.72B |
| 1-day change | -3.96% | -3.27% |
| YTD return | -19.69% | -24.28% |
| 1-year return | -19.84% | -13.49% |
| Forward P/E | 19.46 | — |
| EPS (TTM) | $-0.82 | $-2.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $586.32M | — |
| Revenue growth (YoY) | +19.74% | — |
| Net income (latest FY) | $27.92M | $-131.12M |
| Gross margin | 59.82% | — |
| Operating margin | 13.34% | — |
| Net margin | 4.76% | — |
| 52-week high | $6.53 | $53.65 |
| 52-week low | $2.94 | $21.95 |
| Distance from 52-week high | -36.91% | -41.53% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +82.04% | +99.11% |
| Average volume | 1.13M | 737.14K |
| Shares outstanding | 356.82M | 54.68M |
| Employees | 1,279 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Alvotech
ALVO stock →Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,279 employees
About Maze Therapeutics
MAZE stock →Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
ALVO vs MAZE FAQ
Which is bigger, Alvotech or Maze Therapeutics?
Maze Therapeutics (MAZE) is larger, with a market capitalization of $1.72B compared with $1.47B for Alvotech (ALVO).
Which stock has performed better over the past year, ALVO or MAZE?
MAZE returned -13.49% over the past 12 months, compared with -19.84% for ALVO (price return, excluding dividends). Past performance does not predict future results.
Are Alvotech and Maze Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.